Clinical trials: Hindgut Neuroendocrine Tumor
Neuroendocrine Tumors
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
Clinical data from uncontrolled retrospective or prospective studies have initially demonstrated antiproliferative effects of lanreotide in limited number of patients lanreotide Autogel® has recently been approved in more than 40…
- Trial name
- NCT03083210
- Testing
- Lanreotide
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center